Neonatal Sepsis
Conditions
Brief summary
Hypothesis: Orally ingested lactoferrin has effects on promotion of growth and differentiation of the immature gut; also it has immunomodulatory properties, so it will prevent serious infections in preterm infants. The aim of the study is to: * Evaluate the effectiveness of oral lactoferrin in prevention of neonatal sepsis. * Compare two dose regiment of lactoferrin supplementation. * Study effect of lactoferrin supplementation on serum iron stores. It is a prospective, randomized, double blind, placebo-controlled study, it will include 180 preterm neonates admitted to the Neonatal Intensive Care Units of of Ain Shams University Hospitals and Manshiet El Bakry Hospital. •Group A: Who will receive oral lactoferrin supplementation in a dose of 100 mg/day. •Group B: Who will receive oral lactoferrin supplementation in a dose of 150 mg/kg/ twice daily. •Group C (Controls): Who match the subjected neonates, will receive placebo in form of distilled water.
Interventions
DIETARY_SUPPLEMENTLactoferrin
dose of 100 mg/day
DIETARY_SUPPLEMENTPlacebo
in form of distilled water
Sponsors
Mooselmokadem
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 28 Days
Healthy volunteers
Yes
Inclusion criteria
1. Neonates with a birth weight between 500g and 2500g. 2. Neonates with a ≤ 36 weeks of gestation counting from the first day of the Last Menstrual Period. 3. Preterm neonates born in, or referred to the Neonatal Intensive Care Units of one of the participating hospitals in the first 48 hours of life.
Exclusion criteria
1. Neonates with underlying gastrointestinal problems that prevent oral intake. 2. Neonates with predisposing conditions that profoundly affect growth and development (chromosomal abnormalities, structural brain anomalies, severe congenital abnormalities). 3. Neonates with a family background of cow milk allergy. 4. Neonates who will not have the chance to complete the study time (who will be referred to another hospitals). 5. Neonates whose parents decline to participate. 6. Neonates with early onset sepsis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood culture | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Complete blood count with differential leucocytic count. | 2 years |
Other
| Measure | Time frame |
|---|---|
| C reactive protein quantitative assay | 2 years |
Countries
Egypt
Contacts
Primary ContactMostafa AM Elmokadem, Master
Outcome results
None listed